Altre lingue Quoin Pharmaceuticals, Ltd.

Azioni

QNRX

US74907L3006

Tempo reale stimato Cboe BZX Altri mercati azionari 18:42:05 30/04/2024			Variaz. 5gg	Var. 1 gen.
0,7 ^USD	+2,17%		+7,42%	-85,55%

15/03	QUOIN PHARMACEUTICALS, LTD. : prospettiva positiva di Maxim	ZM
14/03	Quoin Pharmaceuticals cerca opportunità di M&A	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Quoin Pharmaceuticals Seeks M&A Opportunities	14/03
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	13/03
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results	13/03
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET	07/03
ADRs Close Higher; Dada Nexus Ltd. Climbs 30%	06/03
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	05/03
Top Midday Decliners	05/03
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall	05/03
Top Premarket Decliners	05/03
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering	05/03
Top Midday Gainers	04/03
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial	04/03
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	04/03
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	04/03
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome	15/02
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	08/02
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	08/02
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $8 million in funding from Alumni Capital LP	25/01
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	18/12
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	13/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Quoin Pharmaceuticals, Ltd.

Azioni

QNRX

US74907L3006

Altre lingue

Filtri